AAVantgarde Bio has secured $141 million in Series B financing to advance clinical programs for Stargardt disease and Usher syndrome, underscoring the demand for innovative therapies in the inherited retinal disease sector.
Target Information
AAVantgarde Bio (AAVantgarde) is a clinical-stage biotechnology company that focuses on developing innovative therapies for inherited retinal diseases (IRDs), particularly targeting Stargardt disease and Usher syndrome type 1B. Recently, the company successfully closed a $141 million (€122 million) Series B financing round, co-led by Schroders Capital and supported by existing investors such as Atlas Venture and Forbion.
The financing will be used to advance promising clinical programs, including the AAVB-039 CELESTE study, which aims to address the genetic mutations causing Stargardt disease, and the AAVB-081 LUCE trial for retinitis pigmentosa stemming from Usher syndrome. Both studies are critical as they target the underlying genetic causes of these diseases, which currently lack approved therapies.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target's Specific Country
The biotechnology sector in the UK and Europe has experienced substantial growth in recent years, driven by increasing investment in healthcare innovation and a surge in demand for therapies for rare diseases
Similar Deals
Schroders Capital
invested in
AAVantgarde Bio
in 2025
in a Series B deal
Disclosed details
Transaction Size: $141M